|
| 36791667 | A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). | Eur J Cancer | 2023 |
| 37752419 | IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience. | BMC Cancer | 2023 |
| 37568703 | Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma. | Cancers (Basel) | 2023 |
| 38074116 | Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines. | Front Pharmacol | 2023 |
| 37478161 | USP1 Expression Driven by EWS::FLI1 Transcription Factor Stabilizes Survivin and Mitigates Replication Stress in Ewing Sarcoma. | Mol Cancer Res | 2023 |
| 37474760 | EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis. | Commun Biol | 2023 |
| 36771452 | The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling. | Nutrients | 2023 |
| 36765545 | Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research. | Cancers (Basel) | 2023 |
| 36796283 | Corrigendum to "SELNET clinical practice guidelines for soft tissue sarcoma and GIST" [Cancer Treat. Rev. 102 (2021) 102312]. | Cancer Treat Rev | 2023 |
| 36614241 | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma. | Int J Mol Sci | 2023 |
| 36791667 | A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl). | Eur J Cancer | 2023 |
| 37353558 | Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. | Cancer Gene Ther | 2023 |
| 36599901 | Profilin 1 deficiency drives mitotic defects and reduces genome stability. | Commun Biol | 2023 |
| 37752419 | IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience. | BMC Cancer | 2023 |
| 38074116 | Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines. | Front Pharmacol | 2023 |
| 37568703 | Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma. | Cancers (Basel) | 2023 |
| 37353558 | Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. | Cancer Gene Ther | 2023 |
| 37474760 | EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis. | Commun Biol | 2023 |
| 37478161 | USP1 Expression Driven by EWS::FLI1 Transcription Factor Stabilizes Survivin and Mitigates Replication Stress in Ewing Sarcoma. | Mol Cancer Res | 2023 |
| 36614241 | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma. | Int J Mol Sci | 2023 |
| 36771452 | The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling. | Nutrients | 2023 |
| 36765545 | Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research. | Cancers (Basel) | 2023 |
| 36796283 | Corrigendum to "SELNET clinical practice guidelines for soft tissue sarcoma and GIST" [Cancer Treat. Rev. 102 (2021) 102312]. | Cancer Treat Rev | 2023 |
| 36599901 | Profilin 1 deficiency drives mitotic defects and reduces genome stability. | Commun Biol | 2023 |
| 34667115 | Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity. | Mol Cancer Ther | 2022 |
| 35712255 | Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response. | Front Endocrinol (Lausanne) | 2022 |
| 35460913 | SELNET clinical practice guidelines for bone sarcoma. | Crit Rev Oncol Hematol | 2022 |
| 36171618 | Correction: Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells. | Clin Epigenetics | 2022 |
| 36358827 | CIC-Rearranged Sarcomas: An Intriguing Entity That May Lead the Way to the Comprehension of More Common Cancers. | Cancers (Basel) | 2022 |
| 36236019 | A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response. | Polymers (Basel) | 2022 |
| 36233089 | Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing. | Int J Mol Sci | 2022 |
| 36352194 | Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis. | Cell Oncol (Dordr) | 2022 |
| 36220678 | Corrigendum to "SELNET clinical practice guidelines for bone sarcoma" Critical reviews in oncology/hematology, vol. 174 (2022), 1-10. | Crit Rev Oncol Hematol | 2022 |
| 35566091 | Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells. | Molecules | 2022 |
| 36149602 | ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis. | Cell Oncol (Dordr) | 2022 |
| 36338681 | Polymorphic variants of <i>IGF2BP3</i> and <i>SENCR</i> have an impact on predisposition and/or progression of Ewing sarcoma. | Front Oncol | 2022 |
| 35740530 | Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. | Cancers (Basel) | 2022 |
| 35422060 | Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma. | Cell Death Dis | 2022 |
| 35406534 | miR-214-3p Is Commonly Downregulated by EWS-FLI1 and by CD99 and Its Restoration Limits Ewing Sarcoma Aggressiveness. | Cancers (Basel) | 2022 |
| 34985580 | Does PAX7 and NKX2.2 immunoreactivity in Ewing sarcoma have prognostic significance? | Virchows Arch | 2022 |
| 34667115 | Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity. | Mol Cancer Ther | 2022 |
| 34903601 | Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. | Cancer Res | 2022 |
| 35172717 | miR-486-5p expression is regulated by DNA methylation in osteosarcoma. | BMC Genomics | 2022 |
| 35201621 | Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2). | Cancer | 2022 |
| 35740530 | Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. | Cancers (Basel) | 2022 |
| 35406534 | miR-214-3p Is Commonly Downregulated by EWS-FLI1 and by CD99 and Its Restoration Limits Ewing Sarcoma Aggressiveness. | Cancers (Basel) | 2022 |
| 35460913 | SELNET clinical practice guidelines for bone sarcoma. | Crit Rev Oncol Hematol | 2022 |
| 35422060 | Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma. | Cell Death Dis | 2022 |
| 35566091 | Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells. | Molecules | 2022 |
| 35712255 | Novel Targeting of DNA Methyltransferase Activity Inhibits Ewing Sarcoma Cell Proliferation and Enhances Tumor Cell Sensitivity to DNA Damaging Drugs by Activating the DNA Damage Response. | Front Endocrinol (Lausanne) | 2022 |